Abstract:Radiometals play an important role in the diagnosis of physiological processes in vivo by means of imaging technologies, but also increasingly contribute to the treatment of diseases. The by far dominant way to apply the advantages of nuclear transformations of radiometals is the use of radiometalligand complexes. In this context, it turns out that DOTA (and its derivatives) currently is the most potent chelator. This article reviews the physico-chemical properties of DOTA and its [*M(DOTA)]complexes, which ma… Show more
“…Additionally, the high concentration of HCl not only converted 68 Ga-colloids into ionic [ 68 Ga]Ga 3+ travelling with the solvent front. Besides that, it seemed to facilitate the H + -assisted dissociation of the DOTA complex [ 47 , 48 , 49 ].…”
The novel compound 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-ZOL (DOTA-conjugated zoledronic acid) is a promising candidate for the diagnosis and therapy of bone metastasis. The combination of the published methodology for this bisphosphonate with pharmaceutical and regulatory requirements turned out to be unexpectedly challenging. The scope of this work is the presentation and discussion of problems encountered during this process. Briefly, the radiolabelling process and purification, as well as the quality control published, did not meet the expectations. The constant effort setting up an automated radiolabelling procedure resulted in (a) an enhanced manual method using coated glass reactors, (b) a combination of three different reliable radio thin-layer chromatography (TLC) methods instead of the published and (c) a preliminary radio high-pressure liquid chromatography (HPLC) method for identification of the compound. Additionally, an automated radiolabelling process was developed, but it requires further improvement, e.g., in terms of a reactor vessel or purification of the crude product. The published purification method was found to be unsuitable for clinical routine, and an intense screening did not lead to a satisfactory result; here, more research is necessary. To sum up, implementation of DOTA-ZOL was possible but revealed a lot of critical points, of which not all could be resolved completely yet.
“…Additionally, the high concentration of HCl not only converted 68 Ga-colloids into ionic [ 68 Ga]Ga 3+ travelling with the solvent front. Besides that, it seemed to facilitate the H + -assisted dissociation of the DOTA complex [ 47 , 48 , 49 ].…”
The novel compound 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-ZOL (DOTA-conjugated zoledronic acid) is a promising candidate for the diagnosis and therapy of bone metastasis. The combination of the published methodology for this bisphosphonate with pharmaceutical and regulatory requirements turned out to be unexpectedly challenging. The scope of this work is the presentation and discussion of problems encountered during this process. Briefly, the radiolabelling process and purification, as well as the quality control published, did not meet the expectations. The constant effort setting up an automated radiolabelling procedure resulted in (a) an enhanced manual method using coated glass reactors, (b) a combination of three different reliable radio thin-layer chromatography (TLC) methods instead of the published and (c) a preliminary radio high-pressure liquid chromatography (HPLC) method for identification of the compound. Additionally, an automated radiolabelling process was developed, but it requires further improvement, e.g., in terms of a reactor vessel or purification of the crude product. The published purification method was found to be unsuitable for clinical routine, and an intense screening did not lead to a satisfactory result; here, more research is necessary. To sum up, implementation of DOTA-ZOL was possible but revealed a lot of critical points, of which not all could be resolved completely yet.
“…9c and Table 5). 11,53 These examples show that 89 Y chemical shift is highly dependent on its coordination environment with large (B80 ppm) shift differences reported for hyperpolarised 89 Y nuclei coordinated to various different macrocyclic ligands. Such high sensitivity of 89 Y chemical shift to molecular environment has been exploited to design hyperpolarised 89 Y pH sensitive probes.…”
Section: Hyperpolarised 89 Y Complexes As Mri Probesmentioning
confidence: 88%
“…The stability of these metal ion complexes can be increased by synthesising analogues with greater backbone rigidity. 11 For example, CHX-A 00 -DTPA is a common derivative of DTPA that contains a rigid cyclohexane group in the DTPA backbone resulting in an increase in log K from 22.5 to 24.7 for Y-DTPA and Y-CHX-A 00 -DTPA respectively. 12 The geometry of the Y 3+ complex is also affected by CN and ligand denticity.…”
Section: Common Ligands Used For Coordination To Yttriummentioning
Yttrium presents a wide palette of isotopes with interesting coordination and radiochemical properties. We review its most prominent isotopes and their diverse medical uses in therapy and imaging.
“…NOTA has the smaller chelating cavity of the two, and is generally used for Ga (III) or Cu (II) because it has a particular attraction for these metals, which results in mild radiolabeling conditions and good in vivo stability of the complexes formed. DOTA (which is considered as the gold standard chelator) and its derivatives play an important role in clinical applications because they form very stable complexes with a wide range of trivalent radiometals such as Ga (III), Y (III), In (III), Lu (III), or even divalent such as Cu (II) [ 57 , 58 ]. For DOTA or NOTA, the introduction of a functionalized arm offers the possibility of coupling a biomolecule (NODASA/NODAGA and DOTASA/DOTAGA).…”
Section: Targeting Of Somatostatin Receptors With Radiopharmaceutimentioning
Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five subtypes described. The interaction between SST and its receptors leads to the internalization of the ligand–receptor complex and triggers different cellular signaling pathways. Interestingly, the expression of SSTRs is significantly enhanced in many solid tumors, especially gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). Thus, somatostatin analogs (SSAs) have been developed to improve the stability of the endogenous ligand and so extend its half-life. Radiolabeled analogs have been developed with several radioelements such as indium-111, technetium-99 m, and recently gallium-68, fluorine-18, and copper-64, to visualize the distribution of receptor overexpression in tumors. Internal metabolic radiotherapy is also used as a therapeutic strategy (e.g., using yttrium-90, lutetium-177, and actinium-225). With some radiopharmaceuticals now used in clinical practice, somatostatin analogs developed for imaging and therapy are an example of the concept of personalized medicine with a theranostic approach. Here, we review the development of these analogs, from the well-established and authorized ones to the most recently developed radiotracers, which have better pharmacokinetic properties and demonstrate increased efficacy and safety, as well as the search for new clinical indications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.